A novel lymphocyte transformation test (LTT-MELISA) for Lyme borreliosis
| Autor: | Martin Sandkamp, Elizabeth Valentine-Thon, Karsten Ilsemann |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Microbiology (medical)
Adult Male Lymphocyte medicine.disease_cause Borrelia afzelii Lymphocyte Activation Sensitivity and Specificity Lyme disease Antigen Bacterial Proteins Borrelia burgdorferi Group Borrelia medicine Humans Clinical significance Serologic Tests Aged Aged 80 and over Antigens Bacterial Lyme Disease biology Reproducibility of Results General Medicine Middle Aged bacterial infections and mycoses biology.organism_classification medicine.disease Virology Recombinant Proteins Infectious Diseases medicine.anatomical_structure Borrelia burgdorferi Immunology Lyme disease microbiology Borrelia garinii Female |
| Zdroj: | Diagnostic microbiology and infectious disease. 57(1) |
| ISSN: | 0732-8893 |
| Popis: | Diagnosis of active Lyme borreliosis (LB) remains a challenge in clinically ambiguous, serologically indeterminant, and polymerase chain reaction-negative patients. Lymphocyte transformation tests (LTTs) have been applied to detect specific cellular immune reactivity, but their clinical application has been severely hampered by the poorly defined Borrelia antigens and nonstandardized LTT formats used. In this study, we describe the development and clinical relevance of a novel LTT using a validated format (MELISAR) together with well-defined recombinant Borrelia-specific antigens. From an initial screening of 244 patients with suspected Borrelia infection or disease, 4 informative recombinant antigens were selected: OspC (Borrelia afzelii), p41-1 (Borrelia garinii), p41-2 (B. afzelii), and p100 (B. afzelii). Thereafter, 30 seronegative healthy controls were tested in LTT-MELISAR to determine specificity, 68 patients were tested in parallel to determine reproducibility, and 54 lymphocyte-reactive symptomatic patients were tested before and after antibiotic therapy to assess clinical relevance. Most (86.2%) of the 36.9% (90/244) LTT-MELISAR-positive patients were seropositive and showed symptoms of active LB. Specificity was 96.7% and reproducibility 92.6%. After therapy, most patients (90.7%) showed negative or markedly reduced lymphocyte reactivity correlating with clinical improvement. This novel LTT-MELISAR assay appears to correlate with active LB and may have diagnostic relevance in confirming LB in clinically and serologically ambiguous cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect